Glenmark Pharma

{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,364.35",
    "chg": -6.7,
    "chgp": "-0.28%",
    "dir": -1,
    "prev_price": "2,371.05",
    "mcapval": "65,739.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE935A01035",
    "curr_date": "May 08",
    "curr_time": "",
    "bse_nse_vol": "7.15 lacs",
    "exc_status": "Active",
    "traded_date": "May 08, 2026",
    "traded_date_str": "2026 05 08",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "SM",
      "url": "https://www.marketsmojo.com/mojopro/stock-of-the-month",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Glenmark Pharmaceuticals Ltd. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-glenmark-pharmaceuticals-ltd-fallingrising-3976609",
        "imagepath": "",
        "date": "2026-05-06 01:54:36",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Financial Fundamentals Driving Investor Confidence</strong></p>\n<p>Glenmark Pharmaceuticals has demonstrated exceptional financial performance in the latest six-month period ending December 2025. Net sales surged to ₹9,947.49 crores, marking a substantial growth of 45.83%. Profit after tax (PAT) also showed a significant increase, reaching ₹2,026.77 crores. These figures underscore the company’s ability to generate strong earnings, which has been a key factor in bolstering investor sentiment.</p>\n<p>The company’s return on capital employed (ROCE) for the half-year stands at an impressive 35.65%, indicating efficient utilisation of capital to generate profits. Additionally, Glenmark’s return on equity (ROE) of 23.5% highlights its capacity to deliver attractive returns to shareholders...."
      },
      {
        "title": "Glenmark Pharmaceuticals Gains 4.68%: 4 Key Factors Driving the Week’s Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-gains-468-4-key-factors-driving-the-weeks-rally-3971653",
        "imagepath": "",
        "date": "2026-05-02 15:04:27",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>27 Apr:</strong> Stock opens at Rs.2,324.85 with positive momentum</p>\n                    <p><strong>28 Apr:</strong> New 52-week high and all-time high at Rs.2,374 and Rs.2,364.10 respectively</p>\n                    <p><strong>29 Apr:</strong> Further 52-week and all-time high at Rs.2,471.05, marking third consecutive day of gains</p>\n                    <p><strong>30 Apr:</strong> Slight profit-taking closes week at Rs.2,405.55 (-0.21% on day)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,324.85</div></div>\n                    <div class=\"stat-it..."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. is Rated Strong Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-ltd-is-rated-strong-buy-3972071",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_mojoScore_3972071.png",
        "date": "2026-05-01 10:10:29",
        "description": "Glenmark Pharmaceuticals Ltd. is rated 'Strong Buy' by MarketsMOJO, with this rating last updated on 08 Apr 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 May 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Glenmark Pharmaceuticals Ltd. to 52-Week High of Rs 2471.05",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-hits-new-52-week-high-at-rs247105-3967804",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/GlenmarkPharmac_priceRelatedfactors_3967804.png",
        "date": "2026-04-29 09:43:47",
        "description": "Surging to a fresh 52-week and all-time high of Rs 2471.05 on 29 Jun 2026, Glenmark Pharmaceuticals Ltd. has demonstrated remarkable price momentum, outpacing its sector and the broader market with a 77.00% gain over the past year. This rally is underpinned by a confluence of bullish technical indicators and sustained upward price action across multiple timeframes."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Hits All-Time High of Rs 2,471.05 as Momentum Builds Across Timeframes",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-stock-hits-all-time-high-at-rs-247105-3967764",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/GlenmarkPharmac_priceRelatedfactors_3967764.png",
        "date": "2026-04-29 09:34:52",
        "description": "Extending its winning streak to three sessions, Glenmark Pharmaceuticals Ltd. surged to a fresh all-time high of Rs 2,471.05 on 29 Apr 2026, outperforming the broader Sensex by 1.26 percentage points. This milestone caps a remarkable run where the stock has gained 6.57% over the past three days amid heightened volatility and strong technical signals."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Glenmark Pharmaceuticals Ltd. to 52-Week High of Rs 2374",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-hits-new-52-week-high-at-rs2374-3966116",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/GlenmarkPharmac_priceRelatedfactors_3966116.png",
        "date": "2026-04-28 09:44:11",
        "description": "Surging to an all-time high of Rs 2,374 on 28 Apr 2026, Glenmark Pharmaceuticals Ltd. has demonstrated remarkable price momentum, outpacing its sector and the broader market with a 68.75% gain over the past year. This milestone reflects a confluence of strong technical signals and sustained upward price action that has captured investor attention."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Hits All-Time High of Rs 2,364 as Momentum Builds Across Timeframes",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-stock-hits-all-time-high-on-28-april-2026-3966069",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/GlenmarkPharmac_priceRelatedfactors_3966069.png",
        "date": "2026-04-28 09:35:14",
        "description": ""
      },
      {
        "title": "Glenmark Pharmaceuticals Gains 2.23%: 6 Key Factors Driving the Week’s Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-gains-223-6-key-factors-driving-the-weeks-momentum-3962591",
        "imagepath": "",
        "date": "2026-04-25 15:04:36",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Apr 20:</strong> Stock opens at Rs.2,229.65, down 0.81%</p>\n                    <p><strong>Apr 21:</strong> Modest recovery with Rs.2,232.95 close (+0.15%)</p>\n                    <p><strong>Apr 22:</strong> Continued gains to Rs.2,241.55 (+0.39%)</p>\n                    <p><strong>Apr 23:</strong> New 52-week and all-time highs at Rs.2,322.75 and Rs.2,312.15; sharp open interest surge</p>\n                    <p><strong>Apr 24:</strong> Further 52-week high at Rs.2,371.6; mixed price action with open interest rising 19.5%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=..."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-3961166",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/GlenmarkPharmac_oi_spurts_by_underlying_3961166.png",
        "date": "2026-04-24 15:00:47",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant 19.5% surge in open interest in its derivatives segment, signalling heightened market activity and evolving positioning among traders. Despite a modest price decline of 1.14% on 24 Apr 2026, the stock remains buoyant above key moving averages, reflecting a complex interplay between bullish sentiment and short-term profit-taking."
      }
    ],
    "total": 535,
    "sid": "780863",
    "stock_news_url": "https://www.marketsmojo.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "30-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Glenmark Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24299MH1977PLC019982</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>AA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>CRISIL LTD.</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>NSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Harish Kuber <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: Harish.Kuber@glenmarkpharma.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Anurag Mantri <br/> Designation: Executive Director and Global Chief Financial Officer <br/> EmailId: Anurag.Mantri@glenmarkpharma.com</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2",
      "datetime": "30-Apr-2026",
      "details": "<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Glenmark Pharmaceuticals Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24299MH1977PLC019982</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Harish Kuber</td></tr><tr><td>Designation :-</td><td>Company Secretary and Compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Anurag Mantri</td></tr> <tr><td>Designation : -</td><td>Executive Director and Global Chief Financial Officer</td></tr></table><div> <br/> Date: 30/04/2026<br/><br/></div>",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "09-Apr-2026",
      "details": "Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts 100 mg",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 03 Oct 25",
          "dt": "2025-10-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Glenmark Pharmaceuticals Ltd. falling/rising?

2026-05-06 01:54:36

Strong Financial Fundamentals Driving Investor Confidence

Glenmark Pharmaceuticals has demonstrated exceptional financial performance in the latest six-month period ending December 2025. Net sales surged to ₹9,947.49 crores, marking a substantial growth of 45.83%. Profit after tax (PAT) also showed a significant increase, reaching ₹2,026.77 crores. These figures underscore the company’s ability to generate strong earnings, which has been a key factor in bolstering investor sentiment.

The company’s return on capital employed (ROCE) for the half-year stands at an impressive 35.65%, indicating efficient utilisation of capital to generate profits. Additionally, Glenmark’s return on equity (ROE) of 23.5% highlights its capacity to deliver attractive returns to shareholders....

Read full news article

Glenmark Pharmaceuticals Gains 4.68%: 4 Key Factors Driving the Week’s Rally

2026-05-02 15:04:27

Key Events This Week

27 Apr: Stock opens at Rs.2,324.85 with positive momentum

28 Apr: New 52-week high and all-time high at Rs.2,374 and Rs.2,364.10 respectively

29 Apr: Further 52-week and all-time high at Rs.2,471.05, marking third consecutive day of gains

30 Apr: Slight profit-taking closes week at Rs.2,405.55 (-0.21% on day)

Week Open

Rs.2,324.85

Read full news article

Glenmark Pharmaceuticals Ltd. is Rated Strong Buy

2026-05-01 10:10:29

Glenmark Pharmaceuticals Ltd. is rated 'Strong Buy' by MarketsMOJO, with this rating last updated on 08 Apr 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 May 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Broad-Based Technical Strength Lifts Glenmark Pharmaceuticals Ltd. to 52-Week High of Rs 2471.05

2026-04-29 09:43:47

Surging to a fresh 52-week and all-time high of Rs 2471.05 on 29 Jun 2026, Glenmark Pharmaceuticals Ltd. has demonstrated remarkable price momentum, outpacing its sector and the broader market with a 77.00% gain over the past year. This rally is underpinned by a confluence of bullish technical indicators and sustained upward price action across multiple timeframes.

Read full news article

Glenmark Pharmaceuticals Ltd. Hits All-Time High of Rs 2,471.05 as Momentum Builds Across Timeframes

2026-04-29 09:34:52

Extending its winning streak to three sessions, Glenmark Pharmaceuticals Ltd. surged to a fresh all-time high of Rs 2,471.05 on 29 Apr 2026, outperforming the broader Sensex by 1.26 percentage points. This milestone caps a remarkable run where the stock has gained 6.57% over the past three days amid heightened volatility and strong technical signals.

Read full news article

Broad-Based Technical Strength Lifts Glenmark Pharmaceuticals Ltd. to 52-Week High of Rs 2374

2026-04-28 09:44:11

Surging to an all-time high of Rs 2,374 on 28 Apr 2026, Glenmark Pharmaceuticals Ltd. has demonstrated remarkable price momentum, outpacing its sector and the broader market with a 68.75% gain over the past year. This milestone reflects a confluence of strong technical signals and sustained upward price action that has captured investor attention.

Read full news article

Glenmark Pharmaceuticals Ltd. Hits All-Time High of Rs 2,364 as Momentum Builds Across Timeframes

2026-04-28 09:35:14

Read full news article

Glenmark Pharmaceuticals Gains 2.23%: 6 Key Factors Driving the Week’s Momentum

2026-04-25 15:04:36

Key Events This Week

Apr 20: Stock opens at Rs.2,229.65, down 0.81%

Apr 21: Modest recovery with Rs.2,232.95 close (+0.15%)

Apr 22: Continued gains to Rs.2,241.55 (+0.39%)

Apr 23: New 52-week and all-time highs at Rs.2,322.75 and Rs.2,312.15; sharp open interest surge

Apr 24: Further 52-week high at Rs.2,371.6; mixed price action with open interest rising 19.5%

Week Open

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action

2026-04-24 15:00:47

Glenmark Pharmaceuticals Ltd. has witnessed a significant 19.5% surge in open interest in its derivatives segment, signalling heightened market activity and evolving positioning among traders. Despite a modest price decline of 1.14% on 24 Apr 2026, the stock remains buoyant above key moving averages, reflecting a complex interplay between bullish sentiment and short-term profit-taking.

Read full news article

View All News